It is shocking that a commissioner would choose to resign rather than watch an agency's bipartisan tradition crumble in front of her eyes.
Our bill has guardrails. It does not give FTC any new power or regulatory authority.
It requires the FTC to study pharmaceutical intermediaries and issue a report and recommendations to Congress within one...
Any true attempt at understanding the factors driving costs must include a look at the broader supply chain.
improved information sharing between CBP and its private-sector partners would aid efforts to identify and curtail the s...
the rise of global e-commerce presents profound new challenges for the responsibility of governments to collect revenue ...
Our investigation found that the PBM scheme encourages drug makers to spike the drug's list price in order to offer a gr...
PBMs are blocking a cheaper product.
I have long had concerns with the FTC's vague statutory authority, but at this moment, we cannot ignore the current stat...
The Cantwell-Grassley PBM Transparency Act directs the FTC to end well-known and documented PBM practices that drive up ...